Form 4: enGene Holdings CFO Acquires 280,000 Stock Options

enGene Holdings' Chief Financial Officer, D. Ryan Daws, was granted 280,000 stock options on January 29, 2025.

Summary

• D. Ryan Daws, the Chief Financial Officer of enGene Holdings Inc., acquired 280,000 stock options on January 29, 2025.
• The options have an exercise price of $7.39 per share.
• The options vest monthly over 48 months, contingent on Daws' continued service with the company.
• The options expire on January 29, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in publicly traded companies, particularly in the biotechnology sector, to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in publicly traded companies.
• The vesting schedule of 48 months is typical for such grants, ensuring long-term commitment.
• The exercise price of $7.39 is specific to enGene Holdings and would need to be compared to similar companies to assess its competitiveness.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning management's interests with the company's long-term success.
• The vesting schedule encourages the CFO's continued service, which benefits the company and its stakeholders.

Key Dates

Keywords

stock options, executive compensation, insider trading, enGene Holdings, ENGN, CFO, D. Ryan Daws